Fulcrum therapeutics announces proposed public offering of common stock

Cambridge, mass., jan. 17, 2023 (globe newswire) -- fulcrum therapeutics, inc. ® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the public offering. all of the shares in the proposed offering are to be sold by fulcrum.
FULC Ratings Summary
FULC Quant Ranking